

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTEES: Abrams et al.
PATENT NO: 7,404,968
ISSUED: July 29, 2008
FOR: METERING AND PACKAGING OF CONTROLLED
RELEASE MEDICATION
GROUP: 1618 Confirmation No. 3144
EXAMINER: S. Tran DOCKET: MICRODOSE 99.02 CON2

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION FOR CERTIFICATE OF CORRECTION

Dear Sirs:

Abrams et al., the Patentees of the above-identified patent, through their attorney, hereby petition for issuance of a Certificate of Correction in the above identified patent. A Certificate of Correction is enclosed. The Certificate of Correction is required to correct a significant printing error in Claim 12 as follows:


Claim 12, Col. 9, line 31, "more bafflers or" should be --more barriers or--.

Enclosed is a copy of page 5 of Substitute Amendment F filed December 11, 2007, showing claim 12 (previously claim 23). Since the errors were a Patent Office error, it is believed that the Certificate of Correction should be issued without charge to the Applicant.

HAYES SOLOWAY P.C.
3450 E. SUNRISE DRIVE,
SUITE 140
TUCSON, AZ 85718
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567

Respectfully submitted,



Norman P. Soloway
Attorney for Patentees
Reg. No. 24,315

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this paper is being deposited with the United States Patent Office
via the electronic filing procedure on February 3, 2010 at
Tucson, Arizona.



NPS:pt/sb

HAYES SOLOWAY P.C.
3450 E. SUNRISE DRIVE,
SUITE 140
TUCSON, AZ 85718
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,404,968
APPLICATION NO.: 10/756,124
ISSUE DATE : July 29, 2008
INVENTOR(S) : Abrams et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 12, Col. 9, line 31, "more bafflers or" should be --more barriers or--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Norman P. Soloway
HAYES SOLOWAY P.C.
3450 E. Sunrise Drive, Suite 140, Tucson, Arizona 85718

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

powdered pharmaceutical ingredients at two or more different selected sites within a patient's alimentary canal,

wherein said two or more powdered pharmaceutical ingredients are deposited on said membrane, separated from one another by one or more barriers or membranes, and wherein said two or more powdered pharmaceutical ingredients are selected from the group consisting of Ketoconazole and testosterone; Valacylovir and one or both of Cimetidine and Probenecid; Enalapril and a beta-adrenergic blocking agent, methyldopa, nitrate, a calcium blocking agent, hydrazine, Prazosin or Digoxin; Omeprazole and B12; Tamoxifen and a diuretic; Isotretinoin and an oral contraceptive; and Metformin HCl and Sulfonyleurea.

Claim 24 (new): A pharmaceutical delivery package according to claim 22, wherein said ingestible membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 25 (new): A pharmaceutical delivery package according to claim 23, wherein said ingestible membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 26 (new): A pharmaceutical delivery package according to claim 5, wherein said ingestible membrane comprises an alkali-dissolvable or acid-dissolvable material.

Claim 27 (new): A pharmaceutical delivery package according to claim 21, wherein said membrane is formed into a tablet or capsule.

Claim 28 (new): A pharmaceutical delivery package according to claim 21, wherein said powdered pharmaceutical ingredients are segregated from one another in a compartmentalized capsule.

Claim 29 (new): A pharmaceutical delivery package according to claim 22, wherein said membrane is formed into a tablet or capsule.